Home Patent Forecast® Sectors Log In   Contact  
How it works Patent Forecast® Sectors Insights
Menu
Enjoy your FREE PREVIEW which shows only 2022 data and 25 documents. Contact Patent Forecast for full access.        

AI Biotech/Diagnostics: Cardio

Search All Patents in AI Biotech/Diagnostics: Cardio


Patent US10266901


Issued 2019-04-23

Methods Of Monitoring Conditions By Sequence Analysis

There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer. Provided herein are methods for using DNA sequencing to identify personalized biomarkers in patients with autoimmune disease and other conditions. Identified biomarkers can be used to determine the disease state for a subject with an autoimmune disease or other condition.



Much More than Average Length Specification


View the Patent Matrix® Diagram to Explore the Claim Relationships

USPTO Full Text Publication >

1 Independent Claim

  • 1. A method for determining a profile of recombined T cell receptor (TCR) and/or immunoglobulin (IG) DNA sequences in a sample comprising T cells and/or B cells comprising: a) amplifying said recombined TCR and/or IG DNA sequences in the sample by polymerase chain reaction (PCR) using a set of amplification primers, wherein said amplification primers comprise a generic primer sequence; b) spatially isolating individual molecules of amplified recombined TCR and/or IG DNA comprising generic primer sequences; c) amplifying the spatially isolated individual molecules of amplified recombined TCR and/or IG DNA by PCR using primers specific for the generic primer sequences wherein said primers specific for the generic primer sequence comprise a sequencing adaptor sequence; d) sequencing said recombined TCR and/or IG DNA sequences by synthesis using reversible terminated labeled nucleotides to provide at least 1000 sequence reads each having an error rate and each comprising at least 30 base pairs so that different clonotypes of said sample are determined from sequence reads with a confidence of at least 99.9 percent based on the error rate; and e) determining the levels of different clonotypes in the sample to generate a profile of clonotypes of recombined DNA sequences.